C J Guico-Pabia

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders
    C J Guico-Pabia
    Pfizer Inc, Collegeville, PA, USA
    Curr Med Res Opin 27:1815-26. 2011
  2. doi request reprint Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis
    Christine J Guico-Pabia
    Pfizer Inc, Collegeville, Pennsylvania 19426, USA
    Int Clin Psychopharmacol 27:1-7. 2012

Detail Information

Publications2

  1. doi request reprint Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders
    C J Guico-Pabia
    Pfizer Inc, Collegeville, PA, USA
    Curr Med Res Opin 27:1815-26. 2011
    ..This post hoc analysis examined efficacy and tolerability of open-label desvenlafaxine in patients with major depressive disorder switched from blinded placebo, venlafaxine extended release (ER), or desvenlafaxine...
  2. doi request reprint Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis
    Christine J Guico-Pabia
    Pfizer Inc, Collegeville, Pennsylvania 19426, USA
    Int Clin Psychopharmacol 27:1-7. 2012
    ..A better understanding of the relationship between depressive symptoms and functional impairment and well-being may provide clinicians with a more comprehensive means of assessing treatment effects in major depressive disorder...